PMID: 8946658Dec 1, 1996Paper

Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy

Therapeutic Drug Monitoring
S StewartJ D Horowitz

Abstract

We tested the hypothesis that resolution versus persistence of symptomatic ischaemia and/or development of nausea/dizziness on the third day of loading with perhexiline maleate (PM), is correlated with perhexiline plasma concentrations after the standard loading phase in patients with acute coronary syndromes. Forty consecutive patients with either unstable angina pectoris or non-Q-wave myocardial infarction with persistent angina pectoris, despite maximal pharmacological therapy (other than PM), were studied. All patients received PM 400 mg/day for 3 days and 200 mg/day thereafter. On days 2 and 3 observers blinded to the 72-96 h plasma perhexiline concentration assessed the patient regarding episodes of angina and/or nausea/dizziness. On the third day of loading with PM, 12 patients experienced angina and 11 patients had nausea and/or dizziness. Plasma perhexiline concentrations at 72-96 h varied widely: mean 0.46 +/- 0.26 (range 0.11-1.77) microgram/ml. There was a relationship of borderline statistical significance between resolution of anginal symptoms and plasma perhexiline concentration > 0.15 microgram/ml (p = 0.055). There was a close relationship between emergence of nausea/dizziness with plasma perhexiline concentrat...Continue Reading

References

Nov 27, 1978·European Journal of Clinical Pharmacology·E SinglasP Simon
Jan 1, 1989·European Journal of Clinical Pharmacology·L P BalantC von Bahr
Nov 1, 1986·International Journal of Cardiology·J D HorowitzW J Louis
May 1, 1983·International Journal of Cardiology·H D White, J B Lowe
Jan 30, 1982·British Medical Journal·R R ShahJ D Lockhart
Feb 1, 1984·Journal of Medical Genetics·R G CooperE J Whibley
Mar 1, 1981·Journal of Pharmaceutical Sciences·J D HorowitzW J Louis
Apr 1, 1995·Australian and New Zealand Journal of Medicine·J D HorowitzL Wing

❮ Previous
Next ❯

Citations

Oct 17, 1998·European Journal of Pharmacology·S R WilloughbyJ D Horowitz
May 20, 1999·European Journal of Pharmacology·J A KennedyJ D Horowitz
Jun 13, 2001·Journal of the American College of Cardiology·Y Y ChirkovJ D Horowitz
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·S M Killalea, H Krum
Sep 4, 2007·Pharmacology & Therapeutics·Yuliy Y Chirkov, John D Horowitz
Mar 5, 2004·British Journal of Clinical Pharmacology·Terry E JonesJohn D Horowitz
Mar 18, 2004·British Journal of Clinical Pharmacology·Benjamin J L DaviesBenedetta C Sallustio
Apr 21, 2007·Cardiovascular Drug Reviews·Houman AshrafianMichael P Frenneaux
Jan 18, 2006·European Journal of Pharmacology·Jennifer A KennedyJohn D Horowitz
Sep 18, 2015·European Journal of Clinical Pharmacology·Cher-Rin ChongBenedetta C Sallustio
Apr 8, 2015·Breast Cancer Research : BCR·Xiu-Rong RenWei Chen
Apr 24, 2016·Cardiovascular Drugs and Therapy·Cher-Rin ChongJohn D Horowitz
Jul 28, 2016·Expert Opinion on Therapeutic Patents·Christopher H GeorgeZaheer Yousef
Feb 14, 2006·European Journal of Cardiovascular Nursing : Journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology·Sally Inglis, Simon Stewart
May 21, 2019·Expert Opinion on Pharmacotherapy·Nida WaheedCarl J Pepine
Sep 14, 2006·Pharmacological Reviews·Sharon J Gardiner, Evan J Begg
Feb 11, 2012·Therapeutic Drug Monitoring·Harel GilutzJohn D Horowitz
Jan 22, 2002·Therapeutic Drug Monitoring·R HusseinR L Rasiah

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.